Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Autism
Published in: Molecular Autism 1/2016

Open Access 01-12-2016 | Research

Brinp1 −/− mice exhibit autism-like behaviour, altered memory, hyperactivity and increased parvalbumin-positive cortical interneuron density

Authors: Susan R. Berkowicz, Travis J. Featherby, Zhengdong Qu, Aminah Giousoh, Natalie A. Borg, Julian I. Heng, James C. Whisstock, Phillip I. Bird

Published in: Molecular Autism | Issue 1/2016

Login to get access

Abstract

Background

BMP/RA-inducible neural-specific protein 1 (Brinp1) is highly conserved in vertebrates, and continuously expressed in the neocortex, hippocampus, olfactory bulb and cerebellum from mid-embryonic development through to adulthood.

Methods

Brinp1 knock-out (Brinp1 −/−) mice were generated by Cre-recombinase-mediated removal of the third exon of Brinp1. Knock-out mice were characterised by behavioural phenotyping, immunohistochemistry and expression analysis of the developing and adult brain.

Results

Absence of Brinp1 during development results in a behavioural phenotype resembling autism spectrum disorder (ASD), in which knock-out mice show reduced sociability and changes in vocalisation capacity. In addition, Brinp1 −/− mice exhibit hyper-locomotor activity, have impaired short-term memory, and exhibit poor reproductive success.
Brinp1 −/− mice show increased density of parvalbumin-expressing interneurons in the adult mouse brain. Brinp1 −/− mice do not show signs of altered neural precursor proliferation or increased apoptosis during late embryonic brain development. The expression of the related neuronal migration genes Astn1 and Astn2 is increased in the brains of Brinp1 −/− mice, suggesting that they may ameliorate the effects of Brinp1 loss.

Conclusions

Brinp1 plays an important role in normal brain development and function by influencing neuronal distribution within the cortex. The increased cortical PV-positive interneuron density and altered behaviour of Brinp1 −/− mice resemble features of a subset of human neurological disorders; namely autism spectrum disorder (ASD) and the hyperactivity aspect of attention deficit hyperactivity disorder (ADHD).
Appendix
Available only for authorised users
Literature
1.
2.
3.
Weiss LA. Autism genetics: emerging data from genome-wide copy-number and single nucleotide polymorphism scans. Expert Rev Mol Diagn. 2009;9(8):795–803.CrossRefPubMed
4.
Folstein SE, Rosen-Sheidley B. Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet. 2001;2(12):943–55.CrossRefPubMed
5.
Fombonne E. Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry. 2005;66 Suppl 10:3–8.PubMed
6.
Brugha TS et al. Epidemiology of autism spectrum disorders in adults in the community in England. Arch Gen Psychiatry. 2011;68(5):459–65.CrossRefPubMed
7.
First, M.B. and APA, DSM-5 handbook of differential diagnosis. First edition. ed. 2013. xv, 322 pages.
8.
Tek S et al. Longitudinal analyses of expressive language development reveal two distinct language profiles among young children with autism spectrum disorders. J Autism Dev Disord. 2014;44(1):75–89.CrossRefPubMedPubMedCentral
9.
McGonigle-Chalmers M et al. Profound expressive language impairment in low functioning children with autism: an investigation of syntactic awareness using a computerised learning task. J Autism Dev Disord. 2013;43(9):2062–81.CrossRefPubMed
10.
Rybakowski F et al. Autism spectrum disorders—epidemiology, symptoms, comorbidity and diagnosis. Psychiatr Pol. 2014;48(4):653–65.PubMed
11.
Tureck K et al. An examination of the relationship between autism spectrum disorder, intellectual functioning, and comorbid symptoms in children. Res Dev Disabil. 2014;35(7):1766–72.CrossRefPubMed
12.
Simonoff E et al. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921–9.CrossRefPubMed
13.
Wohr M et al. Lack of parvalbumin in mice leads to behavioral deficits relevant to all human autism core symptoms and related neural morphofunctional abnormalities. Transl Psychiatry. 2015;5:e525.CrossRefPubMedPubMedCentral
14.
Lawrence YA et al. Parvalbumin-, calbindin-, and calretinin-immunoreactive hippocampal interneuron density in autism. Acta Neurol Scand. 2010;121(2):99–108.CrossRefPubMed
15.
Vogt D et al. The parvalbumin/somatostatin ratio is increased in Pten mutant mice and by human PTEN ASD alleles. Cell Rep. 2015;11(6):944–56.CrossRefPubMed
16.
Rossignol E. Genetics and function of neocortical GABAergic interneurons in neurodevelopmental disorders. Neural Plast. 2011;2011:649325.PubMedPubMedCentral
17.
Marin O. Interneuron dysfunction in psychiatric disorders. Nat Rev Neurosci. 2012;13(2):107–20.PubMed
18.
19.
Kondos SC et al. The structure and function of mammalian membrane-attack complex/perforin-like proteins. Tissue Antigens. 2010;76(5):341–51.CrossRefPubMed
20.
Kawano H et al. Identification and characterization of novel developmentally regulated neural-specific proteins, BRINP family. Brain Res Mol Brain Res. 2004;125(1–2):60–75.CrossRefPubMed
21.
Terashima M et al. Analysis of the expression and function of BRINP family genes during neuronal differentiation in mouse embryonic stem cell-derived neural stem cells. J Neurosci Res. 2010;88(7):1387–93.PubMed
22.
Kobayashi M et al. Absence of BRINP1 in mice causes increase of hippocampal neurogenesis and behavioral alterations relevant to human psychiatric disorders. Mol Brain. 2014;7:12.CrossRefPubMedPubMedCentral
23.
Wood WE et al. Dietary retinoic acid affects song maturation and gene expression in the song system of the zebra finch. Dev Neurobiol. 2008;68(10):1213–24.CrossRefPubMed
24.
Lovell PV, et al. Birdsong “Transcriptomics”: Neurochemical Specializations of the Oscine Song System. 2008
25.
Beetz C et al. Low expression but infrequent genomic loss of the putative tumour suppressor DBCCR1 in astrocytoma. Oncol Rep. 2005;13(2):335–40.PubMed
26.
Gao S et al. Loss of heterozygosity at 9q33 and hypermethylation of the DBCCR1 gene in oral squamous cell carcinoma. Br J Cancer. 2004;91(4):760–4.PubMedPubMedCentral
27.
Nishiyama H, et al. Negative regulation of G1S transition by the candidate bladder tumour supressor gene DBCCR1. 2001.
28.
Adams NC, et al. Mice that lack astrotactin have slowed neuronal migration. Development, 2002
29.
Wilson PM et al. Astn2, a novel member of the astrotactin gene family, regulates the trafficking of ASTN1 during glial-guided neuronal migration. J Neurosci. 2010;30(25):8529–40.CrossRefPubMedPubMedCentral
30.
Vawter MP, Mamdani F, Macciardi F. An integrative functional genomics approach for discovering biomarkers in schizophrenia. Brief Funct Genomics. 2011;10(6):387–99.CrossRefPubMedPubMedCentral
31.
Do C, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson’s Disease. 2011
32.
Edwards TL et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 2010;74(2):97–109.CrossRefPubMedPubMedCentral
33.
Heinzen EL et al. Genome-wide scan of copy number variation in late-onset Alzheimer’s disease. J Alzheimers Dis. 2010;19(1):69–77.PubMedPubMedCentral
34.
35.
Lionel AC et al. Disruption of the ASTN2/TRIM32 locus at 9q33.1 is a risk factor in males for autism spectrum disorders, ADHD and other neurodevelopmental phenotypes. Hum Mol Genet. 2014;23(10):2752–68.CrossRefPubMedPubMedCentral
36.
Lionel AC et al. Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. Sci Transl Med. 2011;3(95):95ra75.PubMed
37.
38.
39.
Teoh SS et al. A versatile monoclonal antibody specific to human SERPINB5. Hybridoma (Larchmt). 2012;31(5):333–9.CrossRef
40.
41.
Maggio JC, Maggio JH, Whitney G. Experience-based vocalization of male mice to female chemosignals. Physiol Behav. 1983;31(3):269–72.CrossRefPubMed
42.
43.
Hiller MM et al. ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway. Science. 1996;273(5282):1725–8.CrossRefPubMed
44.
Wöhr M. Ultrasonic communication in mouse models of autism. Proceedings of Measuring Behavior 2012
45.
Kordon A et al. Exploring the impact of once-daily OROS(R) methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. Postgrad Med. 2011;123(5):27–38.CrossRefPubMed
46.
Huang FL, Huang KP. Methylphenidate improves the behavioral and cognitive deficits of neurogranin knockout mice. Genes Brain Behav. 2012;11(7):794–805.CrossRefPubMedPubMedCentral
47.
Ishisaka M et al. Diacylglycerol kinase beta knockout mice exhibit attention-deficit behavior and an abnormal response on methylphenidate-induced hyperactivity. PLoS One. 2012;7(5):e37058.CrossRefPubMedPubMedCentral
48.
Hess EJ, Collins CA, Wilson MC. Mouse model of hyperkinesis implicates SNAP-25 in behavioural regulation. J Neurosci. 1996;16:3104–11.PubMed
49.
Scattoni ML, Crawley J, Ricceri L. Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders. Neurosci Biobehav Rev. 2009;33(4):508–15.CrossRefPubMedPubMedCentral
50.
Jamain S et al. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proc Natl Acad Sci U S A. 2008;105(5):1710–5.CrossRefPubMedPubMedCentral
51.
Yang M et al. Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. J Neurosci. 2012;32(19):6525–41.CrossRefPubMedPubMedCentral
52.
Chien SC et al. A new familial insertion, ins(18;9)(q12.2;q33.1q31.1) with a 9q31.1-9q33.1 deletion in a girl with a cleft lip and palate. Am J Med Genet A. 2010;152A(7):1862–7.CrossRefPubMed
53.
van der Meere J et al. Sustained attention, activation and MPH in ADHD: a research note. J Child Psychol Psychiatry. 1995;36(4):697–703.CrossRefPubMed
54.
Contini V et al. Pharmacogenetics of response to methylphenidate in adult patients with attention-deficit/hyperactivity disorder (ADHD): a systematic review. Eur Neuropsychopharmacol. 2013;23(6):555–60.CrossRefPubMed
55.
Giros B et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996;379(6566):606–12.CrossRefPubMed
56.
Bymaster FP et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699–711.CrossRefPubMed
57.
Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34(1):50–4.CrossRefPubMed
58.
Lovett-Barron M et al. Regulation of neuronal input transformations by tunable dendritic inhibition. Nat Neurosci. 2012;15(3):423–30. S1-3.CrossRefPubMed
59.
Enticott PG et al. GABAergic activity in autism spectrum disorders: an investigation of cortical inhibition via transcranial magnetic stimulation. Neuropharmacology. 2013;68:202–9.CrossRefPubMed
60.
Thatcher RW et al. Autism and EEG phase reset: deficient GABA mediated inhibition in thalamo-cortical circuits. Dev Neuropsychol. 2009;34(6):780–800.CrossRefPubMed
61.
Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003;2(5):255–67.CrossRefPubMed
62.
Scacheri PC et al. Bidirectional transcriptional activity of PGK-neomycin and unexpected embryonic lethality in heterozygote chimeric knockout mice. Genesis. 2001;30(4):259–63.CrossRefPubMed
63.
Metadata
Title
Brinp1 −/− mice exhibit autism-like behaviour, altered memory, hyperactivity and increased parvalbumin-positive cortical interneuron density
Authors
Susan R. Berkowicz
Travis J. Featherby
Zhengdong Qu
Aminah Giousoh
Natalie A. Borg
Julian I. Heng
James C. Whisstock
Phillip I. Bird
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Molecular Autism / Issue 1/2016
Electronic ISSN: 2040-2392
DOI
https://doi.org/10.1186/s13229-016-0079-7

Other articles of this Issue 1/2016

Molecular Autism 1/2016 Go to the issue

Research

Bengali translation and characterisation of four cognitive and trait measures for autism spectrum conditions in India

Research

Parent-reported and clinician-observed autism spectrum disorder (ASD) symptoms in children with attention deficit/hyperactivity disorder (ADHD): implications for practice under DSM-5

Research

Altered gaze following during live interaction in infants at risk for autism: an eye tracking study

Research

22q11.2 duplication syndrome: elevated rate of autism spectrum disorder and need for medical screening

Commentary

Data from the Baby Siblings Research Consortium confirm and specify the nature of the female protective effect in autism: A commentary on Messinger et al.

Research

Altered functional organization within the insular cortex in adult males with high-functioning autism spectrum disorder: evidence from connectivity-based parcellation